OneSource Specialty Pharma faced a challenging Q3FY26, with revenue dropping 26% YoY to ₹290.3 Cr and EBITDA plunging 88% YoY to ₹17.3 Cr.

This resulted in an adjusted PAT loss of ₹47.2 Cr, primarily due to delays in Canadian customer approvals for semaglutide and largely fixed operating costs.

Despite the temporary setback, the company reaffirms its FY28 guidance, targeting ₹400-500 Cr in revenue and ~40% EBITDA margins.

OneSource is actively expanding with a $75 million investment in Drug-Device Combination (DDC) capacity, accelerating GLP-1 commercialization.

They've also onboarded a new global biosimilar player, boosting their biologics pipeline, where demand remains robust.

Recent wins include NDA approval for an oncology soft gel product with a major US generics firm.

The effective interest rate improved to below 9%.